Published April 28, 2020
By Mark Henderson
Special to 不良研究所
Read more about 不良研究所 research, teaching and innovative programs in the new听听尘补驳补锄颈苍别.听
A team of researchers, including a pharmacologist at the University of Louisiana Monroe,
has written a study that points to a possible treatment for a variety of cancers,
targeting a mutation in one particular gene.听
The paper has been published online and is featured in the February edition of Molecular
Cancer Therapeutics, the top journal in the cancer therapeutic field.
The research shows that injecting Ceramide-Rubusoside nanomicelles into mice can correct
the mutation in the p53 gene and reverse the cancer process.
听
PHOTO: University of Louisiana Monroe College of Pharmacy pharmacologist Dr. Yong-Yu Liu,
right, working with Ph.D. students Kartik Roy, left, and Sagor Roy, back.
不良研究所 Photo Services
听
Yong-Yu Liu, M.D., Ph.D., a pharmacologist in the 不良研究所 College of Pharmacy, said publication
of the research reflects 10 years of work and holds promise in the treatment of colon,
lung, and ovarian cancers.
鈥淲e know cancer is a common disease, and we know that a key issue is gene mutation,鈥�
Liu said.
Inside the DNA of human cells are thousands of genes, and scientists have identified
triggers for several forms of cancer. 鈥淎nd the No. 1 recent cause of cancer is the
mutation of p53,鈥� according to Liu.
Scientists have known for years about the link between the p53 mutation and cancer.
Toxins in the environment, among these tobacco smoke and ultraviolet light, damage
the gene.
That gene, when healthy, produces a protein that fights off cancer and is known as
a tumor suppressor. A mutation changes the way the gene behaves. In some cases, the
gene simply stops acting as a suppressor. But in 73 percent of the cases, when p53
mutates, Liu said, the result is a missense mutation in which 鈥渢he protein function
changes. It no longer has its anticancer function. In fact, it begins to promote cancer,鈥�
Liu said. And 42 percent of all cancers are linked to the mutation.
Its role in causing ovarian cancer, however, is what concerns Liu and others on the
research team the most.
鈥淵ounger women are most prone to get ovarian cancer, and that鈥檚 why we believe it鈥檚
most vital to study it,鈥� He wants to give these victims a chance at a normal life
span.
鈥淲hen you are passionate about what you do, you want to come to a place that lets
you focus on that. I love this place.鈥�
Dr. Yong-Yu Liu
On working at 不良研究所
Medical research takes time, however. Progress is measured in years.
Ten years ago, Liu and his fellow researchers were experimenting with a single cell
with a p53 mutation inside the laboratory when they discovered the introduction of
Ceramide, a metabolite, was able to reverse the mutation.
But the team faced a roadblock in furthering their research.
鈥淐eramide is not water soluble. It cannot mix with water,鈥� Liu said. 鈥淏ecause of that,
we could not get it into the bloodstream.鈥�
For 10 years, the team searched for a solution. Finally, the team determined treating
Ceramide with the natural sugar substitute Rubusoside increased the solubility of
Ceramide, allowing for the injection of nanomicelles into laboratory mice with the
p53 mutation.听
The treatment restored the tumor suppression function of the p53 gene in the mice
while showing no harm to noncancerous cells.
鈥淭hat鈥檚 major progress,鈥� Liu said.
In addition to the publication of the findings, Liu said, the team has applied for
patents with hopes of a pharmaceutical company showing interest in licensing the treatment
for field studies.
听
PHOTO:听Dr. Yong-Yu Liu, a University of Louisiana Monroe College of Pharmacy pharmacologist,
has published his research on gene mutation in the treatment of some cancers.
不良研究所 Photo Services
听
Co-authors of the study with Liu are Sachin K. Khiste, Kartik R. Roy, Mohammad B.
Uddin, Salman B. Hosain and Ronald A. Hill of 不良研究所鈥檚 College of Pharmacy; Zhijun Liu
of LSU Agricultural Center鈥檚 School of Renewable Natural Resources; Xin Gu of LSU鈥檚
Health Sciences Center in Shreveport; and Sami Nazzal of the Department of Pharmaceutical
Sciences at Texas Tech University Health Science Center, Dallas, Texas.
Liu, who was born in China and attended medical school there, studied three years
at the University of Rome, worked in Canada and UCLA before joining 不良研究所鈥檚 faculty,
said the work is not done.
鈥淲e have lots of work to show how our process works. Many won鈥檛 believe it,鈥� Liu said.
He credits 不良研究所 for providing the atmosphere to do his research. 鈥淲hen you are passionate
about what you do, you want to come to a place that lets you focus on that. I love
this place.鈥�
